The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.
endpoints.news/boston-biote...
endpoints.news/boston-biote...
Exclusive: AI Proteins raises $42M Series A, and will launch miniproteins into hub-and-spoke model
AI Proteins raises $42M Series A for minibinder drug development, led by Mission BioCapital & Santé Ventures. CEO Chris Bahl aims to target TNFR1 with first candidate.
endpoints.news
November 18, 2025 at 3:55 PM
The next chapter for AI Proteins @aiproteins.com is officially underway! I'm absolutely delighted to share that we’ve closed a $41.5M Series A led by Mission BioCapital and Santé Ventures.
endpoints.news/boston-biote...
endpoints.news/boston-biote...
BIOCAPITAL!!!!! OMG
Was that guy secretly Vox…??
Was that guy secretly Vox…??
July 19, 2025 at 8:11 PM
BIOCAPITAL!!!!! OMG
Was that guy secretly Vox…??
Was that guy secretly Vox…??
Friends and colleagues in Berlin, welcome to join our colloquium on [Against] Animal Capitalism at Art Laboratory Berlin on February 18th. In my talk "Animals, Biocapital and Left Politics" I focus on the notion of nonhuman labour and biocapital as central drivers of accumulation in capitalism.
IN-PROGRESS… | COLLOQUIUM - Art Laboratory Berlin
The Colloquium addresses an international interdisciplinary research audience to present and discuss past, present or future projects by artists, scholars, curators or editors from the fields of art, ...
artlaboratory-berlin.org
February 9, 2025 at 2:06 PM
Friends and colleagues in Berlin, welcome to join our colloquium on [Against] Animal Capitalism at Art Laboratory Berlin on February 18th. In my talk "Animals, Biocapital and Left Politics" I focus on the notion of nonhuman labour and biocapital as central drivers of accumulation in capitalism.
This looks relevant to faunal aDNA as well (e.g. use in opaque commercial enterprises that intersect with palaeogenomic research)
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
DNA samples taken from prehistoric bones from Europe are now used to explain some of the complex social and cultural processes of the past. But data intensive research is changing how archaeologist...
www.tandfonline.com
March 18, 2026 at 9:07 AM
This looks relevant to faunal aDNA as well (e.g. use in opaque commercial enterprises that intersect with palaeogenomic research)
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
👇
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
www.tandfonline.com/doi/full/10....
Obsidian Therapeutics ($OBX): new 6.6% holder
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Paradigm Biocapital Advisors LP: 6.6% of Obsidian Therapeutics ($OBX)
Schedule 13G filed Oct 5. Who filed, the stake, and how it changed.
elixstocks.com
October 5, 2026 at 8:02 PM
Obsidian Therapeutics ($OBX): new 6.6% holder
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Paradigm Biocapital Advisors: 0 → 6.6%
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 5
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
All set for an exciting day at Biocapital Europe in Amsterdam #Inverna #BioCapital2026 #Biotech #RNA #SpliceModulation #Neurodegeneration #ParkinsonsDisease #HuntingtonsDisease #PrecisionMedicine #BiotechInvesting #Partnering
March 4, 2026 at 7:15 AM
All set for an exciting day at Biocapital Europe in Amsterdam #Inverna #BioCapital2026 #Biotech #RNA #SpliceModulation #Neurodegeneration #ParkinsonsDisease #HuntingtonsDisease #PrecisionMedicine #BiotechInvesting #Partnering
Samsara BioCapital has backed dozens of companies in life sciences, and it's now trying to raise a $200M opportunity fund.
endpoints.news/samsara-bioc...
endpoints.news/samsara-bioc...
Samsara BioCapital eyes $200M opportunity fund
Samsara BioCapital seeks to raise $200M for opportunity fund, having secured $98M from 19 investors. Firm has made 180+ investments since 2017, including Abcuro and Dewpoint.
endpoints.news
October 10, 2025 at 3:04 PM
Samsara BioCapital has backed dozens of companies in life sciences, and it's now trying to raise a $200M opportunity fund.
endpoints.news/samsara-bioc...
endpoints.news/samsara-bioc...
invented symbolic artifact due to artifactual cultural rules that could be entirely changed and contribute basically nothing to biocapital maintenance and replication. and so on.
September 26, 2026 at 5:11 PM
invented symbolic artifact due to artifactual cultural rules that could be entirely changed and contribute basically nothing to biocapital maintenance and replication. and so on.
$PMVP — Officer Change
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
October 5, 2026 at 3:46 PM
$PMVP — Officer Change
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
PMV Pharmaceuticals appointed Matt Eckler, Ph.D., a Principal at Samsara BioCapital, to its Board of Directors. The company is planning to submit a New Drug Application (NDA) for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian can...
🧵 continued ↓
108 BioCapital Invests $4 Million in SedMed for Expanding Accessibility Solutions#United_States#Danbury#Accessibility_Solutions #108_BioCapital#SedMed_Toilet_Lift
108 BioCapital Invests $4 Million in SedMed for Expanding Accessibility Solutions
108 BioCapital has announced a substantial $4 million investment in SedMed, aimed at enhancing its innovative non-electric toilet lift solutions for individuals with mobility challenges.
third-news.com
October 1, 2026 at 4:09 PM
108 BioCapital Invests $4 Million in SedMed for Expanding Accessibility Solutions#United_States#Danbury#Accessibility_Solutions #108_BioCapital#SedMed_Toilet_Lift
AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.
See the official press release for details:
www.businesswire.com/news/home/20...
See the official press release for details:
www.businesswire.com/news/home/20...
November 20, 2025 at 8:02 PM
AI Proteins has closed a $41.5 million Series A financing to accelerate the development of de novo #miniproteins! The round was led by Mission BioCapital and SANTÉ, with robust participation from existing investors.
See the official press release for details:
www.businesswire.com/news/home/20...
See the official press release for details:
www.businesswire.com/news/home/20...
Good morning #biosky! Another reverse merger today. Here we have Kalaris Therapeutics, a start-up founded by Samsara BioCapital, merging with Allovir. It will advance Kalaris' next-gen anti-VEGF for AMD, now in Ph1 (data 3Q25); has ~$100m cash, runway to 4Q26: www.globenewswire.com/news-release...
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and...
www.globenewswire.com
November 8, 2024 at 12:16 PM
Good morning #biosky! Another reverse merger today. Here we have Kalaris Therapeutics, a start-up founded by Samsara BioCapital, merging with Allovir. It will advance Kalaris' next-gen anti-VEGF for AMD, now in Ph1 (data 3Q25); has ~$100m cash, runway to 4Q26: www.globenewswire.com/news-release...
#Biotech VC Firm Midwest BioCapital Launches: www.madisonstartups.com/biotech-vc-f...
#venturecapital
#venturecapital
Biotech VC Firm Midwest BioCapital Launches - Startup and Tech News - Madison Startups
Midwest BioCapital, a venture capital firm that invests in early-stage biotech and life science startups, recently announced its launch.
www.madisonstartups.com
October 10, 2025 at 4:13 PM
#Biotech VC Firm Midwest BioCapital Launches: www.madisonstartups.com/biotech-vc-f...
#venturecapital
#venturecapital
Could add, on top of expectations lit, lit with a focus on promissory aspects of tech, e.g. Sunder Rajan's Biocapital.
September 7, 2024 at 7:04 PM
Could add, on top of expectations lit, lit with a focus on promissory aspects of tech, e.g. Sunder Rajan's Biocapital.
October 5: Matt Eckler of Samsara BioCapital joins the board. The NDA for rezatapopt in TP53 Y220C ovarian cancer is still planned for Q1 2027.
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
PMV $PMVP: Rezatapopt Data, NDA And Warrant Reset
PMV stock hub: rezatapopt ovarian responses, Q4 2026 data, Q1 2027 NDA plan, cash runway, September financing, warrant reset and dated short interest.
www.merlintrader.com
October 6, 2026 at 9:32 AM
October 5: Matt Eckler of Samsara BioCapital joins the board. The NDA for rezatapopt in TP53 Y220C ovarian cancer is still planned for Q1 2027.
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
PMV Pharmaceuticals (#$PMVP): Can Rezatapopt Build on Ovarian Responses?
www.merlintrader.com/pmv-pharmace...
Paradigm Biocapital Advisors LP disclosed a 5.1% stake in Spyre Therapeutics ($SYRE), worth about $397M.
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
Paradigm Biocapital Advisors LP: 5.1% of Spyre Therapeutics ($SYRE)
Filed Oct 1. Who filed, the stake, and how it changed.
elixstocks.com
October 1, 2026 at 8:07 PM
Paradigm Biocapital Advisors LP disclosed a 5.1% stake in Spyre Therapeutics ($SYRE), worth about $397M.
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
A 13G is the passive form: a large holder that is not seeking to influence the company.
#Investing #StockMarket #Stocks
Teladoc founder Michael Gorton and Rampart Bioscience's Louis Breton are among the headliners at the Flinn Foundation Bio Capital Conference. Registrations will close soon. Sign up now at www.eventbrite.com/e/flinn-foun... #FlinnBio #TeladocHealth #Biocapital #RampartBioscience
February 10, 2025 at 8:16 PM
Teladoc founder Michael Gorton and Rampart Bioscience's Louis Breton are among the headliners at the Flinn Foundation Bio Capital Conference. Registrations will close soon. Sign up now at www.eventbrite.com/e/flinn-foun... #FlinnBio #TeladocHealth #Biocapital #RampartBioscience
link.growkudos.com/1efi7mdxf5s
@fine-seminar.bsky.social #OpenAccess paper exploring the #Workplace & people's experience of #FertilityTreatment #ART #IVF #HR #Fertility #Policy #Research #Bourdieu #ReproductiveCapital #SocialCapital #EconomicCapital #BioPolitics #BioCapital #SymbolicViolence
@fine-seminar.bsky.social #OpenAccess paper exploring the #Workplace & people's experience of #FertilityTreatment #ART #IVF #HR #Fertility #Policy #Research #Bourdieu #ReproductiveCapital #SocialCapital #EconomicCapital #BioPolitics #BioCapital #SymbolicViolence
Workplace fertility dynamics: how "reproductive capital" shapes lives.
Our paper is based on a study that explored the intricate connection between people's diverse fertility journeys, particularly those involving Assisted Reproductive Technology (ART), and their workpla...
link.growkudos.com
October 17, 2025 at 10:34 PM
link.growkudos.com/1efi7mdxf5s
@fine-seminar.bsky.social #OpenAccess paper exploring the #Workplace & people's experience of #FertilityTreatment #ART #IVF #HR #Fertility #Policy #Research #Bourdieu #ReproductiveCapital #SocialCapital #EconomicCapital #BioPolitics #BioCapital #SymbolicViolence
@fine-seminar.bsky.social #OpenAccess paper exploring the #Workplace & people's experience of #FertilityTreatment #ART #IVF #HR #Fertility #Policy #Research #Bourdieu #ReproductiveCapital #SocialCapital #EconomicCapital #BioPolitics #BioCapital #SymbolicViolence
The next meeting - Eco-Ability RG - is on Fri 2 May. We'll discuss Kelly Fritsch's (2017). "Toxic pregnancies: Speculative futures, disabling environments, and neoliberal biocapital"
Open access PDF: www.researchgate.net/publication/...
Open access PDF: www.researchgate.net/publication/...
(PDF) Toxic pregnancies: Speculative futures, disabling environments, and neoliberal biocapital
PDF | On Jan 1, 2017, K. Fritsch published Toxic pregnancies: Speculative futures, disabling environments, and neoliberal biocapital | Find, read and cite all the research you need on ResearchGate
www.researchgate.net
April 18, 2025 at 4:22 PM
The next meeting - Eco-Ability RG - is on Fri 2 May. We'll discuss Kelly Fritsch's (2017). "Toxic pregnancies: Speculative futures, disabling environments, and neoliberal biocapital"
Open access PDF: www.researchgate.net/publication/...
Open access PDF: www.researchgate.net/publication/...
Vico CEO Micah Mackison is presenting at BioCapital Europe 2026, sharing updates on VO659 and our global strategy for allele-preferential RNA therapies in polyglutamine diseases. Let’s connect!
#BioCapitalEurope #VO659
#BioCapitalEurope #VO659
March 4, 2026 at 9:25 AM
Vico CEO Micah Mackison is presenting at BioCapital Europe 2026, sharing updates on VO659 and our global strategy for allele-preferential RNA therapies in polyglutamine diseases. Let’s connect!
#BioCapitalEurope #VO659
#BioCapitalEurope #VO659
right!! tbh i tend to read it as a red flag if someone disparages me for my passions lol.. like why would you be trying to get close to me if you didn't want to hear about the things i actually like... could it be you are simply focused on my Biocapital™ as this one creep said to me one time nKDSFKJ
July 19, 2025 at 8:09 PM
right!! tbh i tend to read it as a red flag if someone disparages me for my passions lol.. like why would you be trying to get close to me if you didn't want to hear about the things i actually like... could it be you are simply focused on my Biocapital™ as this one creep said to me one time nKDSFKJ
Just two months after an initial run for capital, David Epstein and team have stapled together a hefty $140 million Series A co-led by OrbiMed, Avoro Capital and Samsara BioCapital.
David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field
David Epstein has retired three times. And he quickly went to work when he got back in the saddle earlier this fall as CEO and chair of Ottimo Pharma, a ...
endpts.com
December 19, 2024 at 9:55 PM
Just two months after an initial run for capital, David Epstein and team have stapled together a hefty $140 million Series A co-led by OrbiMed, Avoro Capital and Samsara BioCapital.
CellsBin Successfully Closes Series A Financing to Enhance Rare-Cell Intelligence Platform#USA#Branford#CellsBin#Rare-Cell_Biology #108_BioCapital
CellsBin Successfully Closes Series A Financing to Enhance Rare-Cell Intelligence Platform
CellsBin has secured Series A financing led by 108 BioCapital to advance its Rare-Cell Intelligence Platform, enhancing precision medicine.
third-news.com
September 22, 2026 at 2:47 PM
CellsBin Successfully Closes Series A Financing to Enhance Rare-Cell Intelligence Platform#USA#Branford#CellsBin#Rare-Cell_Biology #108_BioCapital
A new paper on biological resources by Mathieu Quet
"The extractive loops of biocapital: Venom procurement and antivenom production in India"
journals.sagepub.com/doi/full/10....
"The extractive loops of biocapital: Venom procurement and antivenom production in India"
journals.sagepub.com/doi/full/10....
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
journals.sagepub.com
July 15, 2025 at 10:44 AM
A new paper on biological resources by Mathieu Quet
"The extractive loops of biocapital: Venom procurement and antivenom production in India"
journals.sagepub.com/doi/full/10....
"The extractive loops of biocapital: Venom procurement and antivenom production in India"
journals.sagepub.com/doi/full/10....
A bleak future for ethics.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
A bleak future for ethics. Paleogenomics and the fate of human remains in the age of biocapital
DNA samples taken from prehistoric bones from Europe are now used to explain some of the complex social and cultural processes of the past. But data intensive research is changing how archaeologist...
www.tandfonline.com
March 24, 2026 at 2:02 PM
A bleak future for ethics.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.
Paleogenomics and the fate of human remains in the age of biocapital 🏺🧪
www.tandfonline.com/doi/full/10....
Genomic info detached from notions such as accountability or agency, indirectly placing biologic samples outside of the classic parameters of ethical discussions.